6 results about "Clavulanic acid" patented technology

The invention discloses a combined treatment method and system for potassium clavulanate fermentation waste bacterial liquid and wastewater. According to the method, through the whole-process collaborative design of pretreatment, anaerobic biochemical treatment, biogas desulfurization, sulfur recovery, anaerobic ammonia oxidation, deep biochemical treatment, energy recovery and sludge treatment, the degradation efficiency is improved by adopting ultrasonic wall breaking; the anaerobic ammonia oxidation technology is used for treating low-carbon-nitrogen-ratio and high-ammonia-nitrogen wastewater, the recycled biogas is used for energy supply, elemental sulfur generated by desulfurization replaces an exogenous carbon source, and real-time parameter optimization is achieved in cooperation with a PLC intelligent regulation and control system. The system breaks through a traditional mushroom residue-wastewater step-by-step treatment mode, realizes in-situ harmless treatment and resource utilization of dangerous mushroom residues, solves the problems of high treatment cost, serious secondary pollution, carbon-nitrogen imbalance and the like in the prior art, has the advantages of low energy consumption, low cost, high pollutant removal rate, remarkable resource recovery benefit and the like, and has a wide application prospect. The method is suitable for co-treatment of high-concentration organic wastewater and hazardous waste mushroom dregs in the fermentation pharmaceutical industry.

This invention relates to a compound antibacterial agent and its application in open plant tissue culture. The active ingredients of the compound antibacterial agent include rifampin, kasugamycin, ticarcillin sodium clavulanic acid, and tetrachloroisophthalonitrile. The compound antibacterial agent can synergistically inhibit Agrobacterium rhizogenes or Rhodotorula glutinis, contaminating bacteria that are easily generated during plant tissue culture.

The invention discloses an application of an MSR1 inhibitor in preparation of an anti-tumor immunopotentiator. The MSR1 inhibitor is composed of doxylamine, trafenotide, dexrazoxane and clavulanic acid. The invention discloses application of an MSR1 inhibitor combined with an immune checkpoint inhibitor in preparation of a medicine for treating solid tumors. The MSR1 inhibitor disclosed by the invention is used as an anti-tumor immunopotentiator and is combined with an immune checkpoint inhibitor to treat solid tumors, so that the curative effect of tumor immunotherapy can be improved. The MSR1 inhibitor can induce tumor-related macrophages to be differentiated into anti-tumor subtypes, anti-tumor immunity is driven through phagocytosis and generation of cell factors, and a new method is provided for improving the curative effect of tumor immunotherapy.

The utility model relates to the technical field of chemical equipment, concretely relates to a clavulanic acid purification concentration system to solve the problem of big water consumption and high energy consumption in prior art. The system includes a first ceramic membrane separation unit, a first shunt control unit, a second ultrafiltration membrane separation unit, a second shunt control unit, a third nanofiltration membrane separation unit and a third shunt control unit, and the system is also provided with a three-stage circulation loop, and the flow direction of the concentrated liquid and dialysis liquid output by the membrane separation units at all stages is controlled through the shunt control units at all stages and the multistage circulation loop to improve the purification efficiency, reduce energy consumption and production cost, and ensure the product quality stability.

The invention discloses a pharmaceutical composition for inhibiting CRE and application, and relates to the technical field of drug research and development, and the key points of the technical scheme are as follows: the effect of aztreonam combined with four beta-lactamase inhibitors (avibactam, clavulanic acid, tazobactam and sulbactam) on 77 CRE isolates in Shenzhen children hospitals is evaluated. It is found that most of CRE isolates, resistant to aztreonam, in CRE isolates collected in Shenzhen children hospitals carry MBL and other beta-lactamase genes at the same time. And aztreonam / avibactam has good antibacterial activity on all the tested strains. For isolates which carry MBL genes but do not have AmpC enzyme coding genes, aztreonam / clavulanic acid can be used as a more economical and potential combination therapy regimen than aztreonam / avibactam, but is not suitable for CRE isolates carrying AmpC enzyme genes.

The utility model discloses a clavulanic acid hypha treatment device which comprises a treatment tank and a steam generator, a first steam conveying pipe is connected between the treatment tank and the steam generator, a dehydration structure is connected to the treatment tank, a supporting frame is connected to the dehydration structure, and a five-effect evaporator is connected to the dehydration structure; when the device is used, clavulanic acid and hypha mixed liquid and lime milk can be placed in the treatment tank and are mixed for coagulation and precipitation, and the coagulation and precipitation speed can be increased by adding steam into the steam generator in the process, so that other impurities such as protein and inorganic salt in the clavulanic acid and hypha mixed liquid can be separated, and the clavulanic acid and hypha mixed liquid can be recycled. The method comprises the following steps: firstly, extracting and purifying clavulanic acid, then conveying a mixed solution subjected to coagulation and precipitation to a filter press for solid-liquid separation, and concentrating the separated liquid by using a five-effect evaporator, so that target components such as clavulanic acid and the like are concentrated, and subsequent extraction and purification steps are facilitated.